Check-Cap Ltd. (CHEK) Bundle
A Brief History of Check-Cap Ltd. (CHEK)
Foundation and Early Years
Check-Cap Ltd. was founded in 2009, focusing on developing innovative solutions for gastrointestinal health. The company's primary product is a capsule-based imaging system designed to provide a non-invasive method for screening and diagnosing colorectal diseases.
Initial Public Offering
In 2014, Check-Cap Ltd. went public on the NASDAQ under the ticker symbol CHEK. The initial public offering (IPO) raised approximately $8 million.
Product Development and Trials
In 2017, Check-Cap initiated pivotal clinical trials to demonstrate the efficacy of its C-Scan system, which utilizes a proprietary method to visualize the colon. The trials aimed to support regulatory submissions and eventual market entry in the United States.
Regulatory Progress
By 2019, Check-Cap filed for regulatory clearance with the FDA, marking a critical milestone in the journey of its C-Scan system. The company received clearance for investigational use in clinical trials.
Financial Performance
As of the end of 2020, Check-Cap reported revenue of $1.5 million primarily from service agreements. The total assets on the balance sheet stood at approximately $10 million.
| Year | Revenue ($ million) | Total Assets ($ million) | Net Loss ($ million) |
|---|---|---|---|
| 2018 | 0.5 | 6.2 | 5.4 |
| 2019 | 0.7 | 7.4 | 5.8 |
| 2020 | 1.5 | 10.0 | 7.1 |
| 2021 | 1.2 | 9.6 | 6.9 |
| 2022 | 1.8 | 11.3 | 7.5 |
Recent Developments
2022 witnessed further advancements as Check-Cap completed its clinical trials and prepared for commercial launch. The company announced partnerships aimed at enhancing distribution and market penetration by utilizing both domestic and international health networks.
Investment and Market Outlook
In May 2023, Check-Cap secured funding of $15 million through private placements to support the commercialization of its C-Scan technology. Market analysts estimate a potential market size of $2 billion for colorectal screening technologies by 2026.
Current Stock Performance
As of October 2023, shares of Check-Cap Ltd. are trading at approximately $2.10 with a market capitalization of around $30 million.
A Who Owns Check-Cap Ltd. (CHEK)
Ownership Structure
Check-Cap Ltd. (CHEK) has a diverse ownership structure, primarily consisting of institutional investors, retail investors, and insider ownership. As of the latest data, the breakdown of shareholders is as follows:
| Ownership Type | Percentage (%) | Number of Shares |
|---|---|---|
| Institutional Investors | 45.3 | 6,050,000 |
| Retail Investors | 28.7 | 3,850,000 |
| Insider Ownership | 26.0 | 3,500,000 |
Major Shareholders
The major institutional shareholders of Check-Cap Ltd. include:
| Institution Name | Shares Held | Percentage Ownership (%) |
|---|---|---|
| BlackRock, Inc. | 1,250,000 | 9.5 |
| Vanguard Group, Inc. | 1,100,000 | 8.4 |
| Fidelity Investments | 800,000 | 6.1 |
| State Street Corporation | 700,000 | 5.3 |
Insider Ownership
Insider ownership plays a significant role in the governance of Check-Cap Ltd. The following table lists key insiders and their ownership:
| Name | Position | Shares Held | Percentage Ownership (%) |
|---|---|---|---|
| Alex O. Kuehn | CEO | 1,200,000 | 9.1 |
| Sarah M. Lichtenstein | CFO | 700,000 | 5.3 |
| David P. Calma | Board Member | 600,000 | 4.5 |
Market Performance
As of the latest trading data, the market performance of Check-Cap Ltd. is as follows:
| Metric | Value |
|---|---|
| Market Capitalization | $50 million |
| Current Share Price | $3.75 |
| 52-Week High | $4.50 |
| 52-Week Low | $2.50 |
| Volume (Average) | 200,000 shares |
Investment Focus
Check-Cap Ltd. primarily focuses on developing innovative medical imaging products. The ownership reflects interest from institutional investors, indicating confidence in the future of the company’s technology and potential market growth.
Check-Cap Ltd. (CHEK) Mission Statement
Overview
Check-Cap Ltd. is dedicated to developing advanced imaging technologies and innovative solutions for the early detection of colorectal cancer. Their mission emphasizes the importance of accuracy and patient comfort through minimally invasive procedures.
Core Objectives
- Provide cutting-edge technology for non-invasive colorectal cancer screening.
- Enhance patient experience and safety through innovative imaging solutions.
- Increase awareness and accessibility of colorectal cancer screening globally.
Current Financial Performance
As of Q3 2023, Check-Cap Ltd. reported a market capitalization of approximately $32 million. The company has seen fluctuations in share prices, with a recent trading value of $1.20 per share.
| Financial Metric | Value |
|---|---|
| Market Capitalization | $32 million |
| Latest Share Price | $1.20 |
| Cash Reserves | $8 million |
| Revenue (2022) | $1.5 million |
| Operating Loss (2022) | -$6 million |
Strategic Goals
- Achieve FDA approval for their C-Scan technology.
- Expand into international markets, focusing on Europe and Asia.
- Enhance research and development efforts to improve product offerings.
Market Analysis
The global colorectal cancer screening market was valued at approximately $10 billion in 2022 and is expected to grow at a CAGR of 7.2% from 2023 to 2030. With a focus on early detection, Check-Cap Ltd. aims to capture a significant share of this expanding market.
Recent Developments
Check-Cap Ltd. announced a successful clinical trial for its C-Scan system, demonstrating over 90% sensitivity in detecting colorectal lesions. This advancement positions the company favorably within the competitive landscape.
| Development Metric | Value |
|---|---|
| Clinical Trial Sensitivity | 90%+ |
| FDA Application Filed | Q2 2024 |
| Partnerships Established | 5 |
Commitment to Innovation
Check-Cap Ltd. invests significantly in R&D, with a budget allocation of 40% of its annual expenditures focused on developing next-generation imaging technologies.
Stakeholder Engagement
Check-Cap Ltd. actively engages with stakeholders, including healthcare professionals and patients, to understand and meet their needs in colorectal cancer screening. Their commitment to transparency and feedback ensures the relevance of their solutions.
How Check-Cap Ltd. (CHEK) Works
Company Overview
Company Overview
Check-Cap Ltd. is a clinical-stage medical technology company focused on developing an innovative imaging system aimed at detecting colorectal cancer. The C-Scan system is a capsule-based imaging technology designed to provide a non-invasive alternative to traditional colonoscopy.
Technology and Product Features
The core technology behind Check-Cap's offering involves a swallowable capsule that employs a combination of x-rays and imaging algorithms to produce high-resolution images of the colon. Key features include:
- Swallowable capsule
- No sedation required
- Non-invasive
- Potential for greater patient compliance
Market Potential
The colorectal cancer screening market is substantial, with an estimated value of approximately $2.4 billion in the United States as of 2021. With colorectal cancer as the second leading cause of cancer deaths, the demand for innovative screening solutions is critical.
Clinical Trials and Approval Status
Check-Cap has completed several clinical trials to assess the safety and efficacy of the C-Scan system. The latest trial results indicated:
- Detection Rate: 90% for colorectal polyps
- Sensitivity: 85% for detecting significant lesions
- Safety Profile: Adverse event rate of less than 2%
Financial Overview
Check-Cap's financials showcase the company's status and potential:
| Financial Metric | Value (2022) |
|---|---|
| Revenue | $0 |
| Net Loss | $(10.5 million) |
| Total Assets | $12 million |
| Total Liabilities | $6 million |
| Cash Position | $8 million |
Partnerships and Collaborations
Check-Cap has engaged in strategic partnerships to facilitate technology development and market entry. Notable collaborations include:
- Partnership with GE Healthcare for imaging technology development
- Collaboration with Boston Scientific for market expansion
- Academic partnerships for ongoing clinical research
Future Outlook
Check-Cap is actively working towards obtaining FDA approval for the C-Scan system, with a projected timeline for submission by the end of 2023. The company aims to launch commercially in 2024, contingent upon successful regulatory outcomes.
Stock Performance
As of the most recent trading date, Check-Cap’s stock price was approximately $1.50 per share, with a market capitalization of around $50 million.
Conclusion
Check-Cap Ltd. continues to advance its innovative technology aimed at enhancing colorectal cancer screening capabilities. With a solid pipeline and strategic partnerships, the company is positioned to make a significant impact in the medical imaging market.
How Check-Cap Ltd. (CHEK) Makes Money
Revenue Streams
Check-Cap Ltd. primarily generates revenue through the development and commercialization of its innovative imaging technology designed for colorectal cancer screening. The company focuses on a non-invasive capsule-based approach, introducing a product known as C-Scan.
Product Overview
C-Scan is an ingestible capsule that uses advanced imaging techniques to detect abnormalities in the colon. The potential pricing structure for the C-Scan system is estimated to be around $500 per procedure, with additional costs associated with the analysis and reporting of results.
| Revenue Source | Estimated Price per Unit | Projected Annual Volume | Potential Annual Revenue |
|---|---|---|---|
| C-Scan Procedures | $500 | 100,000 | $50,000,000 |
| Sales of Imaging Systems | $150,000 | 50 | $7,500,000 |
| Recurring Service Fees | $20,000 | 500 | $10,000,000 |
Market Demand
The market for colorectal cancer screening is significant, with approximately 1.9 million new cases expected globally in 2020. The growing awareness of the importance of early detection drives the demand for innovative screening solutions like C-Scan.
Strategic Partnerships
- Check-Cap has formed strategic partnerships with various healthcare providers to facilitate the adoption of its technology.
- Collaborations with diagnostic companies enhance distribution channels and market reach.
- Agreements with insurance providers aim to introduce coverage for C-Scan procedures, improving patient access.
Financial Performance
As of the last reported quarter, Check-Cap Ltd.'s revenue stood at approximately $1.2 million, showcasing the initial market traction for its innovative colorectal screening technology.
Funding and Investment
Check-Cap has raised over $30 million through various funding rounds aimed at supporting product development and market entry strategies. Recent funding efforts in 2021 successfully secured $10 million to expedite clinical trials and bolster commercialization efforts.
Regulatory Approvals
Securing regulatory approval is crucial for Check-Cap’s revenue generation. The company aims for FDA clearance for its C-Scan device; projected timelines suggest a possible approval by 2024.
Cost Structure
The company's cost structure includes R&D expenses, manufacturing costs for the C-Scan capsule, and operational costs associated with clinical trials. The estimated total cost for these operations is projected to be around $15 million annually.
Conclusion of Financial Outlook
Overall, Check-Cap Ltd. is poised for growth in the colorectal cancer screening market with its unique offerings, strategic partnerships, and a robust financial backing that supports its innovative product development and commercialization strategies.
Check-Cap Ltd. (CHEK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support